Nuvation Bio (NUVB) analyst forecast and price target
Analyst forecast
Consensus of 12 analyst ratings
Based on 5 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Aug 21, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $13.00 | Aug 18, 2026 |
| RBC Capital | Maintained | Outperform | $20.00 from $19.00 | Aug 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $21.00 from $17.00 | Jul 27, 2026 |
| Wedbush | Maintained | Outperform | $11.00 | Jul 23, 2026 |
| Truist Securities | Maintained | Buy | $13.00 from $12.00 | Jul 7, 2026 |
| RBC Capital | Maintained | Outperform | $19.00 from $20.00 | Jul 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $17.00 | May 5, 2026 |
| Wedbush | Maintained | Outperform | $11.00 | May 5, 2026 |
| RBC Capital | Maintained | Outperform | $20.00 | May 5, 2026 |
| Wedbush | Maintained | Outperform | $11.00 | Apr 16, 2026 |
| Wedbush | Maintained | Outperform | $11.00 | Apr 2, 2026 |
| Wedbush | Maintained | Outperform | $11.00 | Mar 27, 2026 |
| RBC Capital | Maintained | Outperform | $13.00 from $12.00 | Mar 3, 2026 |
| UBS | Maintained | Neutral | $7.00 from $10.00 | Mar 3, 2026 |
| Wedbush | Maintained | Outperform | $11.00 | Feb 10, 2026 |
| RBC Capital | Maintained | Outperform | $12.00 from $9.00 | Jan 21, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $17.00 from $18.00 | Jan 12, 2026 |
| UBS | Initiated Coverage | Neutral | $10.00 | Jan 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 from $10.00 | Dec 11, 2025 |
Frequently asked questions
What is the price target for NUVB stock?
The average 12-month analyst price target for Nuvation Bio (NUVB) is $15.60, with a high estimate of $21.00 and a low of $11.00, across 5 analysts.
Is NUVB a buy, sell, or hold?
Analysts covering Nuvation Bio currently average a Buy rating: 11 buy, 1 hold and 0 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for NUVB?
The average price target of $15.60 implies 138.71% upside from the last price of $6.54.
What is the latest analyst rating on NUVB?
On Aug 21, 2026, Cantor Fitzgerald initiated coverage of Nuvation Bio at Overweight.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.